The ASEAN rabies veterinary vaccines market size was valued at USD 26.28 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 5.82% from 2023 to 2030. The market is primarily driven by the increasing rabies vaccination coverage for dogs, rising zoonosis concerns, growing government initiatives to eradicate rabies, increasing dog ownership rates, and implementation of mass dog vaccination programs in collaboration with key players and government organizations. For instance, as a part of the rabies control initiative, Global Alliance for Rabies Control (GARC) and Boehringer Ingelheim have organized a mass rabies vaccination program in April 2022, to vaccinate 12,000 animals across the Philippines, Indonesia, Vietnam, and Malaysia.
Rabies remains one of the major concerns in developing countries of Southeast Asia, where stray cats and dogs are seen as abundant. Southeast Asian countries such as Indonesia, the Philippines, Thailand, Myanmar, Vietnam, Cambodia, and Laos are considered to be dog rabies endemic places. Many of these countries have rabies as a notifiable disease in both animals and humans. In response to the current rabies endemic situation, the ASEAN (Association of Southeast Asian Nations) organization is working in collaboration with other animal healthcare organizations to eradicate rabies in ASEAN countries by 2030.
Globally, it has been indicated that the achievement of 70% dog vaccination coverage would bring human rabies cases under control. Vaccinating dogs is regarded to be the most effective approach for controlling, preventing, and eradicating rabies in these countries. Therefore, companies such as Boehringer are collaborating with GARC (Global Alliance for Rabies Control) to provide workshops, surveillance, and support mass animal vaccination programs. As part of the rabies eradication process, the government organizations of ASEAN countries are recommending every pet owner vaccinate their pets against rabies every year or once in three years depending on the type of vaccine.
Furthermore, growing companion animal adoption rates have increased the necessity of rabies vaccination among pets to prevent its transfer to the human population. For instance, in Southeast Asia, Filipinos are considered to be more interested in owning pets with 67% of households in the country owning dogs. The Philippines’ pet searchers population has increased from 6.8 million in 2019 to reach 12.9 million in 2021. However, the country has reported that 99% of its rabies cases are mediated by dogs, which increased dog owners’ concern about the disease burden. Several ASEAN countries have initiated rabies eradication programs to gain rabies-free status by the year 2030.
Developing countries such as Cambodia and Laos have pledged to eradicate rabies among the canine population by 2030, however, they are facing several obstacles. These countries still lack countrywide mass dog vaccination campaigns and adequate dog rabies surveillance programs comparing other ASEAN countries. To overcome such challenges, governments are taking required measures, for instance, the Laos government has announced that they will provide free rabies shots in order to prevent fatal dog rabies cases. These supportive initiatives are anticipated to boost the market growth.
The companion animal segment dominated the market and held a revenue share of over 90.0% in 2022. Rabies is spread through saliva, which means the infection can be transmitted through infected animal bites. Although rabies can be transmitted by monkeys, bats, or, in some cases, cats, 98% of rabies cases are reported to be from rabid dog bites. As the rate of dog adoption increased in the past few years, concerns of pet owners regarding fatal diseases such as rabies are forcing them to vaccinate their dogs and cats on a regular basis. According to an article published by the World Organization for Animal Health (WOAH) in 2020, the transmission period of rabies in household dogs is between 3-7 days before the visualization of clinical symptoms. As the disease is said to have almost 100% mortality, pet owners are volunteering to vaccinate in order to protect their beloved animals.
Rabies poses a serious threat to animal health. It primarily affects livestock through bites from rabid dogs or other infected carnivorous species in wildlife. They are regarded as “dead-end” hosts since they cannot spread the infection. Since many developing nations have an endemic of rabies in livestock, the disease can be identified by clinical symptoms and a history of dog bites. Infected cattle may also pose a disease risk to farmers and veterinarians, which emphasizes the significance of adopting rabies control measures among livestock populations. Furthermore, companies that provide rabies vaccines for livestock animals, such as Zoetis and BroadChem Philippines Biopharma Corporation, are able to maintain a competitive market position. For instance, Zoetis supplies VANGUARD RABIES 1/3-year vaccine for cattle, whereas BroadChem Philippines Biopharma Corporation provides Biocan R vaccine for sheep, goats, pigs, and cattle.
Thailand accounted for the maximum revenue share of more than 18.0% in 2022 owing to the successful implementation of mass vaccination programs and increased animal rabies vaccination coverage. Thailand has long been dedicated to eradicating rabies in accordance with the WHO, OIE, and FAO policy, called “Rabies-free South-East Asia by 2020.” The rabies management program was successful in bringing the number of annual human cases down from a few hundred in the 1960s to under ten between 2011 and 2015. However, in 2016, after the identification of a sudden surge in both animal and human rabies cases, a project called “The Strategies of Animals free of Rabies: Humans are Safe from the Disease, 2017-2020” was established. This rabies eradication program in Thailand achieved great goals.
Cambodia is anticipated to expand at the fastest CAGR over the forecast period owing to the country’s commitment to ‘rabies eradication by 2030’ programs and mass vaccination campaigns that recently gained traction in the country. The national rabies control plan, which has been approved by the Ministry of Health, was developed with assistance from the team at the Institut Pasteur in Cambodia. The current program does not call for routine dog vaccinations; instead, it is focused on enhancing surveillance, improving communication about prevention, acting in areas where rabies virus transmission aspects have been identified, and establishing frontline rabies prevention centers so that populations can be immunized under the necessary circumstances. Mission Rabies will return to Cambodia in May 2023 to build on their initial efforts and vaccinate the entire province of Phnom Penh. These factors are supporting the growth of the market.
The market is consolidated and marked by the existence of a few small- and large-scale manufacturers. However, these players are constantly involved in strategic initiatives, such as new product launches, regional expansions, joint ventures, mergers, and acquisitions, to gain deeper market penetration, thereby maintaining a significant threat for new entrants. For instance, in April 2022, as part of its commitment to sustainable development, Boehringer Ingelheim organized multiple rabies vaccination initiatives across Asia in the year 2022 as part of their commitment to sustainable development. The company aims to vaccinate 12,000 animals across Malaysia, the Philippines, Indonesia, and Vietnam. Some prominent players in the ASEAN Rabies Veterinary Vaccines Market include:
Boehringer Ingelheim International GmbH
Merck & Co., Inc.
Indian Immunologicals Ltd.
BroadChem Philippines Biopharma Corporation
Market size value in 2023
USD 27.59 million
Revenue forecast in 2030
USD 41.01 million
CAGR of 5.82% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million & CAGR from 2023 to 2030
Revenue forecast, company share, competitive landscape, growth factors and trends
Thailand; Vietnam; Cambodia; Indonesia; Laos; Malaysia; Philippines; Myanmar; Rest of ASEAN
Key companies profiled
Boehringer Ingelheim International GmbH; Zoetis; Merck & Co., Inc.; Virbac; Indian Immunologicals Ltd.; BroadChem Philippines Biopharma Corporation
Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the ASEAN rabies veterinary vaccines market report on the basis of application and country:
Application Outlook (Revenue, USD Million, 2018 - 2030)
Country Outlook (Revenue, USD Million, 2018 - 2030)
Rest of ASEAN
b. The ASEAN rabies veterinary vaccines market size was estimated at USD 26.28 million in 2022 and is expected to reach USD 27.59 million in 2023.
b. The ASEAN rabies veterinary vaccines market is expected to grow at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2030 to reach USD 41.01 million by 2030.
b. Thailand dominated the ASEAN rabies veterinary vaccines market with a share of over 18% in 2022. This is attributable to the country's wide implementation of dog rabies vaccination programs and animal rabies eradication measures.
b. Some key players operating in the ASEAN rabies veterinary vaccines market include Boehringer Ingelheim International GmbH; Zoetis; Merck & Co., Inc.; Virbac; Indian Immunologicals Ltd; BroadChem Philippines Biopharma Corporation.
b. Key factors that are driving the ASEAN rabies veterinary vaccines market growth include the increasing rabies vaccination coverage for dogs, rising zoonosis concerns, growing government initiatives to eradicate rabies, and increasing dog ownership rates.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."